Coffee Interaction With the Antihypertensive Drug Felodipine

Sponsor
Lawson Health Research Institute (Other)
Overall Status
Completed
CT.gov ID
NCT02232269
Collaborator
(none)
13
1
4
14.9
0.9

Study Details

Study Description

Brief Summary

Coffee is a globally popular beverage. More than half of the United States population spends an estimated $ 40 billion on the purchase of coffee each year. Personal consumption habits can vary. For example, the frequency of ingestion ranged from 59% for every day to 8% for less than one day per week consumption in one survey. In the case of occasional consumption, coffee can markedly elevate blood pressure in normotensive and hypertensive individuals. This pressor effect can occur with a caffeine dose of 200 - 250 mg, which can be found 2 - 3 cups of coffee. A major active constituent in coffee is caffeine, which is the most widely used pharmacological substance in the world.

Drug therapy plays a major role in the management of hypertension. However, the interaction between coffee or caffeine and blood pressure lowering drugs has been assessed in only three clinical studies that were reported more than three decades ago.

We conducted a comprehensive interaction study involving a commonly ingested amount of a particular Colombian coffee and felodipine in healthy middle-aged men and women. Peripheral (brachial) and central (aortic) hemodynamics and caffeine and felodipine pharmacokinetics were evaluated.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
13 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase 1 Study of the Hemodynamic and Pharmacokinetic Interactions Between Coffee and Felodipine
Study Start Date :
Feb 1, 2012
Actual Primary Completion Date :
Jun 1, 2012
Actual Study Completion Date :
May 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Water plus Felodipine

Felodipine extended-release tablet ,10 mg, single dose, 8 hours

Other: Water

Drug: Felodipine
Other Names:
  • Plendil
  • Renadil
  • Active Comparator: Black Coffee

    Black Coffee, 300 ml, 0 and 1 hour

    Other: Black Coffee

    Experimental: Black Coffee plus Felodipine

    Black Coffee, 300 ml, 0 and 1 hour Felodipine extended-release tablet ,10 mg, single dose, 8 hours

    Other: Black Coffee

    Drug: Felodipine
    Other Names:
  • Plendil
  • Renadil
  • Active Comparator: Grapefruit Juice plus Felodipine

    Grapefruit Juice, 300 ml, 0 and 1 hour Felodipine extended-release tablet ,10 mg, single dose, 8 hours

    Other: Grapefruit Juice

    Drug: Felodipine
    Other Names:
  • Plendil
  • Renadil
  • Outcome Measures

    Primary Outcome Measures

    1. The effect of felodipine on coffee-mediated increases in peripheral and central blood pressure . [Change from Baseline to 8 hours Post Dose]

      Peripheral (brachial systolic and diastolic blood pressure) and central (aortic systolic blood pressure) measurements were the mean of at least 3 readings after 5 minutes of sitting at rest. The respective instruments used were BpTRU™ Vital Signs Monitor (BpTRU Medical Devices, Coquitlam BC, Canada) and SphygmoCor® CP Pulse Wave Analysis System - Research (AtCor Medical, Inc., Itasca, IL USA).

    Secondary Outcome Measures

    1. The effect of coffee on the oral pharmacokinetics of felodipine. [Change from Baseline to 8 hours Post Dose]

      Area Under Curve (AUC) Time Frame: predose, 1,2,3,4,5,6,7,8 hours post-dose

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • healthy (normal physical exam, blood clinical chemistry)

    • willingly signs ethics approved informed consent form

    Exclusion Criteria:
    • history of cardiac, renal, hepatic or gastrointestinal disease or substance abuse

    • significant illness within 2 weeks of starting study

    • history of allergy to felodipine , tablet ingredients or dihydropyridines

    • routinely taking prescription or OTC drugs or natural health products

    • received an investigational drug withing the previous 4 weeks

    • females who are pregnant or breast-feeding

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Victoria Clinical Trials Centre London Ontario Canada

    Sponsors and Collaborators

    • Lawson Health Research Institute

    Investigators

    • Principal Investigator: David G Bailey, BScPhm, PhD, Lawson Health Research Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    David Bailey, Principal Investigator, Lawson Health Research Institute
    ClinicalTrials.gov Identifier:
    NCT02232269
    Other Study ID Numbers:
    • R-11-655
    • NA-7122
    First Posted:
    Sep 5, 2014
    Last Update Posted:
    Aug 13, 2018
    Last Verified:
    Aug 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by David Bailey, Principal Investigator, Lawson Health Research Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 13, 2018